Comparison between abluminal biodegradable polymer ultrathin sirolimus-eluting stent and durable-polymer everolimus-eluting stent (GENOSS randomized clinical trial)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0007397

Enrollment

850

Registered

2022-06-15

Start date

2022-08-01

Completion date

Unknown

Last updated

2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Medical Device : If there is no exclusion criteria for patients suspected or confirmed coronary stenosis and meets the registration criteria, a consent is obtained after the study is explained, and if

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ? 19 years of age or older ? Patients diagnosed with stable coronary artery disease or acute coronary syndrome and with more than 50% coronary stenosis requiring stent insertion ? A person who can voluntarily sign the consent form

Exclusion criteria

Exclusion criteria: ? If the following drugs are irritable or contraindicated (aspirin, clopidogrel, ticagrelor, prasugrel, heparin, sirolimus, or everolimus) ? a pregnant woman ? A person who is expected to have a life expectancy of less than one year due to non-heart disease or less compliant with treatment (as determined by medical judgment by the investigator) ? Patients who refused to participate in the study

Design outcomes

Primary

Measure	Time frame
Cardiac death, target vascular myocardial infarction, and target lesion revascular surgery are synthesized as target lesion failure (TLF).	—

Secondary

Measure	Time frame
Target lesion failure	—

Countries

Korea, Republic of

Contacts

Public ContactSuyoun Shin

Samsung Medical Center

12love26@daum.net+82-2-3410-3694

Outcome results